Calithera Biosciences, Inc. Stock price
Is Calithera Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Calithera Biosciences, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Calithera Biosciences, Inc. forecast:
Analyst Opinions
6 Analysts have issued a Calithera Biosciences, Inc. forecast:
Don't miss a Thing! We will send you all news about Calithera Biosciences, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Dr. Molineaux |
| Employees | 9 |
| Founded | 2010 |
| Website | www.calithera.com |


